Journals / Türk Nöroloji Dergisi / 2017 / Cilt: 23 - Sayı: 3

Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments

Yeni Gelişmeler Işığında Transtiretin İlişkili Ailevi Amiloid Polinöropatisi

Pages
105–111
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although there are still some uncertainties in diagnosing and treating TTR-FAP, recent advances are promising, especially in the field of treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is caused by gain-of-toxic-function of TTR, which dissociates from its native tetramer form to a monomer form and aggregates in several tissues and organs.
📊
Key Findings & Data:Significant improvement has been achieved in treating the disease over the past 20 years, starting with liver transplantation, followed by tetramer stabilizers and TTR-lowering therapies.
💡
Conclusion & Impact:Although there are still some uncertainties in diagnosing and treating TTR-FAP, recent advances are promising, especially in the field of treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is caused by gain-of-toxic-function of TTR, which dissociates from its native tetramer form to a monomer form and aggregates in several tissues and organs. Mutations in the TTR gene lead to this amyloidogenic transformation and cause autosomal dominant disease. TTR-FAP typically causes sensorimotor FAP accompanied by autonomic involvement, but considerable phenotypic diversity is noted between different mutation types. In the event of clinical suspicion, TTR gene sequencing and pathologic confirmation are the recommended paths to follow. Significant improvement has been achieved in treating the disease over the past 20 years, starting with liver transplantation, followed by tetramer stabilizers and TTR-lowering therapies. Although there are still some uncertainties in diagnosing and treating TTR-FAP, recent advances are promising, especially in the field of treatment.

Özet

Transiretin ilişkili ailevi amiloid polinöropatisi (TTR-FAP), vücutta tetramer formda bulunan TTR'nin monomer hale gelerek toksik özellik kazanması ve çeşitli doku ve organlarda birikmesi sonucunda gelişir. TTR genindeki mutasyonlar, proteine amiloidojenik özellik kazandırmakta ve otozomal dominant geçişli hastalığa neden olmaktadır. TTR-FAP tipik olarak otonom tutulumun eşlik ettiği sensorimotor nöropatiye neden olur, ancak farklı mutasyon tipleri arasında ciddi fenotipik farklılık belirtilmiştir. Klinik şüphe halinde genetik ve patolojik inceleme yapılması gerekmektedir. Son 20 yılda, karaciğer transplantasyonu ile başlayan, tetramer stabilizatörlerin ve TTR yapımını baskılayan ilaçların klinik çalışmalarda ciddi etkisinin gösterilmesi ile devam eden süreçte tedavi açısından önemli yol alınmıştır. Hastalığın tanı ve tedavisinde hala bazı belirsizlikler olmakla birlikte, özellikle tedavi alanındaki son gelişmeler ümit vericidir.

🔖

Cite This Article

ÇAKAR, A., DURMUŞ, H. T., DEYMEER, F., SERDAROĞLU, P. O., PARMAN, Y. G. (2022). Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments. Türk Nöroloji Dergisi, Cilt: 23 - Sayı: 3, 105–111. https://ajindex.com/articles/636846

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plante-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31
  2. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-427
  3. Adams D, Theaudin M, Cauquil C, Algalarrondo V, Slama M. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep 2014;14:435
  4. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-423
  5. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062
  6. Sekijima Y, Yoshida K, Tokuda T, Ikeda S. Familial Transthyretin Amyloidosis. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. Gene Reviews(R): Seattle (WA), 1993
  7. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-1300
  8. Rousseau A, Kaswin G, Adams D, Cauquil C, Theaudin M, Mincheva Z, M'Garrech M, Labetoulle M, Barreau E. Ocular involvement in familial amyloid polyneuropathy. J Fr Ophtalmol 2013;36:779-788
  9. Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012;7:1337-1346
  10. Durmuş-Tekçe H, Matur Z, Mert Atmaca M, Poda M, Çakar A, Hıdır Ulaş Ü, Oflazer-Serdaroğlu P, Deymeer F, Parman YG. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTRFAP) in Turkey. Neuromuscul Disord 2016;26:441-446
  11. Riboldi G, Del Bo R, Ranieri M, Magri F, Sciacco M, Moggio M, Bresolin N, Corti S, Comi GP. Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation. Case Rep Neurol 2011;3:62-68
  12. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 2005;12:127-130
  13. Ellie E, Camou F, Vital A, Rummens C, Grateau G, Delpech M, Valleix S. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology 2001;57:135-137
  14. Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, Coelho T; European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: wh